Biogen Q2 2026 revenue beat estimates at $2.74B with adjusted EPS of $3.60, but full-year adjusted EPS guidance was cut to $12–$13 from $14.25–$15.25 due to acquisition-related costs.
FirstSquawk07/29, 05:14 PM
- Rev $2.74B
- est $2.47B
- Leqembi Rev $184M
- est $186.4M
Figures as quoted by FirstSquawk